| Not Yet Recruiting | Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of A NCT07268612 | Emergent BioSolutions | — |
| Not Yet Recruiting | Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Ant NCT03569514 | Emergent BioSolutions | — |
| Recruiting | A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax NCT06365073 | Qin Ning | — |
| Active Not Recruiting | Anthrax AV7909 Boost Evaluation Study NCT05997264 | Biomedical Advanced Research and Development Authority | Phase 2 |
| Unknown | An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis NCT03088111 | Elusys Therapeutics | Phase 4 |
| Terminated | Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System NCT05672875 | SRI International | — |
| Completed | Anthrax AV7909 Liquid vs Lyophilized NCT04660201 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 NCT01624532 | Green Cross Corporation | Phase 2 |
| Completed | Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay NCT04320485 | InBios International, Inc. | — |
| Completed | A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adult NCT04148118 | BlueWillow Biologics | Phase 1 |
| Completed | Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study NCT04067011 | Emergent BioSolutions | Phase 2 |
| Completed | VELOCITY: An Anthrax Vaccine Clinical Study NCT03877926 | Emergent BioSolutions | Phase 3 |
| Completed | Febrile Whole Blood Specimen Collection and Testing NCT03498027 | MRI Global | — |
| Completed | BARDA Securing Anthrax Immunity For the Elderly NCT03518125 | Biomedical Advanced Research and Development Authority | Phase 2 |
| Completed | A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects NCT02655549 | Pfenex, Inc | Phase 1 |
| Completed | PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine NCT02239172 | Fraunhofer, Center for Molecular Biotechnology | Phase 1 |
| Completed | A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels NCT01770743 | Emergent BioSolutions | Phase 2 |
| Completed | Ciprofloxacin BioThrax Co-Administration Study NCT01753115 | Emergent BioSolutions | Phase 2 |
| Completed | Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adu NCT01491607 | Emergent BioSolutions | Phase 3 |
| Completed | Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers NCT01453907 | Elusys Therapeutics | Phase 1 |
| Completed | Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects NCT01265745 | PharmAthene, Inc. | Phase 1 |
| Completed | Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9) NCT01202695 | Emergent BioSolutions | Phase 1 |
| Suspended | Ph1 Study of Valortim and Ciprofloxacin in Humans NCT00964561 | PharmAthene, Inc. | Phase 1 |
| Terminated | Ph1 Study of Valortim and Doxycycline in Humans NCT00964834 | PharmAthene, Inc. | Phase 1 |
| Completed | Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) NCT00845650 | Emergent BioSolutions | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Anthrax Vaccine, GC1109 NCT01867957 | Seoul National University Hospital | Phase 1 |
| Completed | Anthrax Vaccine Clinical Trials NCT00114621 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1 |
| Completed | VHA Clinicians and Bioterror Events: Interactive Web-based Learning NCT00123396 | US Department of Veterans Affairs | N/A |
| Completed | Trial of rPA-102 Vaccine in Healthy Adult Volunteers NCT00100724 | VaxGen | Phase 2 |
| Completed | Anthrax-rPA: Safety, Tolerability, Immunogenicity NCT00063843 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults NCT00057525 | DynPort Vaccine Company LLC, A GDIT Company | Phase 1 |
| Recruiting | Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evalu NCT00050310 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin NCT00031291 | National Institutes of Health Clinical Center (CC) | — |